Skip to Main Content
DownloadHi-Res Photo

Barbara Burtness, MD

Professor of Medicine (Medical Oncology); Interim Associate Cancer Center Director, Diversity, Equity, and Inclusion; Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Leader, Developmental Therapeutics, Yale Cancer Center

Contact Information

Barbara Burtness, MD

Mailing Address

  • Medical Oncology

    25 York Street, PO Box 208028

    New Haven, CT 06520-8028

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Studies of targeted treatments for EGFR expressed head and neck cancers, including biomarkers of resistance and novel strategies such as dual EGFR blockade, to overcome resistance. She leads the ECOG-ACRIN Head and Neck Therapeutics Committee, which conducts large multicenter trials in head and neck cancer, including studies of treatment deintensification in HPV-associated cancer, and molecularly guided post-operative therapy. She chairs multicenter trials of targeted therapy and immunotherapy in head and neck cancer.

Specialized Terms: EGFR expressed head and neck cancers.

Extensive Research Description

Studies of targeted treatments for EGFR expressed head and neck cancers, including biomarkers of resistance and novel strategies such as dual EGFR blockade, to overcome resistance. She has demonstrated that loss of PTEN indicates resistance to EGFR inhibition in head and neck cancer, and studied novel dual EGFR/HDAC inhibitors and combined antibody and tyrosine kinase inhibition as strategies to improve responsiveness to EGFR inhibition. She leads the ECOG-ACRIN Head and Neck Therapeutics Committee, which conducts large multicenter trials in head and neck cancer, and chairs multicenter trials of targeted therapy and immunotherapy in head and neck cancer. Her laboratory studies novel combinatorial therapies to target p53 mutated head and neck cancer.

Coauthors

Research Interests

Drug Therapy; Head and Neck Neoplasms; Medical Oncology; Chemicals and Drugs; Analytical, Diagnostic and Therapeutic Techniques and Equipment

Selected Publications

  • Rape crisis centers.Burtness BA. Rape crisis centers. JAMA 1983, 250: 1391. PMID: 6887453.
  • Fatty acid desaturase specificity of Tetrahymena.Conner RL, Burtness B, Ferguson KA. Fatty acid desaturase specificity of Tetrahymena. Lipids 1984, 19: 285-8. PMID: 6717257, DOI: 10.1007/BF02534456.
  • Oncology and hematology.Burtness BA. Oncology and hematology. JAMA 1995, 273: 1702-3. PMID: 7752426.
  • Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1997, 15: 148-57. PMID: 8996136, DOI: 10.1200/JCO.1997.15.1.148.
  • Histologic markers and long-term prognosis in breast cancer.Burtness BA. Histologic markers and long-term prognosis in breast cancer. The Cancer Journal From Scientific American 1997, 3: 211-2. PMID: 9263626.
  • Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 1998, 4: 1165-75. PMID: 9607574.
  • Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood 1998, 92: 672-82. PMID: 9657770.
  • High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study.Chabannon C, Cornetta K, Lotz JP, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau JP, Sledge G, Novakovitch G, Srour EF, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. British Journal Of Cancer 1998, 78: 913-21. PMID: 9764583, PMCID: PMC2063121, DOI: 10.1038/bjc.1998.601.
  • A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells.Burtness BA, Psyrri A, Rose M, D'Andrea E, Staugaard-Hahn C, Henderson-Bakas M, Clark MB, Mechanic S, Krause D, Snyder E, Cooper RB, Abrantes J, Corringham R, Deisseroth A, Cooper DL. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplantation 1999, 23: 311-5. PMID: 10100573, DOI: 10.1038/sj.bmt.1701589.
  • Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B, Hu GL, Zelterman D, Cooper DL. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.
  • High-dose chemotherapy for the treatment of high-risk and advanced breast cancer.Burtness B. High-dose chemotherapy for the treatment of high-risk and advanced breast cancer. Connecticut Medicine 1999, 63: 41-6. PMID: 10071438.
  • Total-body echo-planar MR imaging in the staging of breast cancer: comparison with conventional methods--early experience.Horvath LJ, Burtness BA, McCarthy S, Johnson KM. Total-body echo-planar MR imaging in the staging of breast cancer: comparison with conventional methods--early experience. Radiology 1999, 211: 119-28. PMID: 10189461, DOI: 10.1148/radiology.211.1.r99ap33119.
  • Preoperative chemoradiation for esophageal cancer.Burtness BA. Preoperative chemoradiation for esophageal cancer. The Cancer Journal From Scientific American 1999, 5: 73-4. PMID: 10198727.
  • Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, Kneuper-Hall R, Farber L, Orell J, Bober-Sorcinelli K, Haffty BG, Reiss M. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. The Cancer Journal From Scientific American 1999, 5: 224-9. PMID: 10439168.
  • Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.Murren JR, Peccerillo K, DiStasio SA, Li X, Leffert JJ, Pizzorno G, Burtness BA, McKeon A, Cheng Y. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemotherapy And Pharmacology 2000, 46: 43-50. PMID: 10912577.
  • Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial.Yanovich S, Mitsky P, Cornetta K, Maziarz RT, Rosenfeld C, Krause DS, Lotz JP, Bitran JD, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-74. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.
  • In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation.Snyder EL, Baril L, Cooper DL, Min K, Mechanic S, Stoddart L, Burtness B, Seagraves P, Debelak J, Gudino M, McCullough J. In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation. Transfusion 2000, 40: 961-7. PMID: 10960524, DOI: 10.1046/j.1537-2995.2000.40080961.x.
  • Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayode K, Forastiere AA. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2000, 18: 868-76. PMID: 10673530, DOI: 10.1200/JCO.2000.18.4.868.
  • Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2000, 18: 904-14. PMID: 10673534, DOI: 10.1200/JCO.2000.18.4.904.
  • The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function.Rose M, Lee FA, Gollerkeri A, D'Andrea E, Psyrri A, Bdolah-Abram T, Burtness BA. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplantation 2000, 26: 133-9. PMID: 10918422, DOI: 10.1038/sj.bmt.1702449.
  • A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. Cancer Journal (Sudbury, Mass.) 2000, 6: 309-15. PMID: 11079170.
  • Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience.Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. International Journal Of Cancer. Journal International Du Cancer 2001, 93: 139-41. PMID: 11391633, DOI: 10.1002/ijc.1295.
  • Phase I study of perillyl alcohol in patients with refractory malignancies.Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I study of perillyl alcohol in patients with refractory malignancies. Cancer Biology & Therapy 2002, 1: 130-5. PMID: 12170772, DOI: 10.4161/cbt.57.
  • Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biology & Therapy 2002, 1: 646-51. PMID: 12642688, DOI: 10.4161/cbt.314.
  • Sequential high-dose alkylating therapy and stem cell support for high-risk stage III breast cancer.Bou-Khalil J, Rose M, Psyrri A, D'Andrea E, Medoff E, Staugaard-Hahn C, Holtkamp C, Gran S, Pezzimente J, Snyder E, Cooper D, Haffty B, Reiss M, Burtness B. Sequential high-dose alkylating therapy and stem cell support for high-risk stage III breast cancer. The Breast Journal 2003, 9: 472-7. PMID: 14616941, DOI: 10.1046/j.1524-4741.2003.09604.x.
  • Surgical treatment of esophageal cancer.Knisely JP, Burtness BA, Salem RR. Surgical treatment of esophageal cancer. The New England Journal Of Medicine 2003, 348: 1177-9; author reply 1177-9. PMID: 12647729.
  • Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. International Journal Of Radiation Oncology, Biology, Physics 2003, 56: 328-34. PMID: 12738305, DOI: 10.1016/s0360-3016(02)04598-4.
  • Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology 2003, 10: 132-9. PMID: 12673177, DOI: 10.1067/mnc.2003.7.
  • Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 6461-8. PMID: 14695149.
  • Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 3061-9. PMID: 15284256, DOI: 10.1200/JCO.2004.01.108.
  • A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftment.Angelopoulou MK, Rinder H, Wang C, Burtness B, Cooper DL, Krause DS. A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftment. Transfusion 2004, 44: 555-66. PMID: 15043572, DOI: 10.1111/j.1537-2995.2004.03285.x.
  • Improved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients.Alvero AB, Burtness BA, Ercan AG, Sapi E. Improved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients. Laboratory Investigation; A Journal Of Technical Methods And Pathology 2004, 84: 658-61. PMID: 15105816, DOI: 10.1038/labinvest.3700086.
  • Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA. Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology 2005, 69: 372-83. PMID: 16319508, DOI: 10.1159/000089991.
  • Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2005, 11: 5856-62. PMID: 16115926, DOI: 10.1158/1078-0432.CCR-05-0420.
  • Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature.Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clinical Colorectal Cancer 2005, 5: 283-6. PMID: 16356307, DOI: 10.3816/ccc.2005.n.041.
  • Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 17-23. PMID: 15545666, DOI: 10.1200/JCO.2005.09.048.
  • Pregnancy-associated breast cancer.Psyrri A, Burtness B. Pregnancy-associated breast cancer. Cancer Journal (Sudbury, Mass.) 2005, 11: 83-95. PMID: 15969981, DOI: 10.1097/00130404-200503000-00001.
  • Images in clinical medicine. Cetuximab-associated acneiform eruption.Moss JE, Burtness B. Images in clinical medicine. Cetuximab-associated acneiform eruption. The New England Journal Of Medicine 2005, 353: e17. PMID: 16282170, DOI: 10.1056/NEJMicm050560.
  • The role of cetuximab in the treatment of squamous cell cancer of the head and neck.Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opinion On Biological Therapy 2005, 5: 1085-93. PMID: 16050785, DOI: 10.1517/14712598.5.8.1085.
  • Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 8646-54. PMID: 16314626, DOI: 10.1200/JCO.2005.02.4646.
  • Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.Burtness B. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5440-2. PMID: 16009959, DOI: 10.1200/JCO.2005.02.002.
  • Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Of Today (Barcelona, Spain : 1998) 2005, 41: 107-27. PMID: 15821783, DOI: 10.1358/dot.2005.41.2.882662.
  • Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. International Journal Of Surgical Pathology 2005, 13: 319-27. PMID: 16273187, DOI: 10.1177/106689690501300403.
  • Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion On Biological Therapy 2006, 6: 951-62. PMID: 16918262, DOI: 10.1517/14712598.6.9.951.
  • Novel targets in pancreatic cancer: focus on future paths to therapy.Cohen SJ, Burtness BA. Novel targets in pancreatic cancer: focus on future paths to therapy. Expert Opinion On Therapeutic Targets 2006, 10: 771-5. PMID: 16981833, DOI: 10.1517/14728222.10.5.771.
  • Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer Journal (Sudbury, Mass.) 2006, 12: 212-21. PMID: 16803680, DOI: 10.1097/00130404-200605000-00010.
  • Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray.Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006, 106: 1677-84. PMID: 16532435, DOI: 10.1002/cncr.21783.
  • Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs 2006, 24: 135-40. PMID: 16502351, DOI: 10.1007/s10637-006-5934-5.
  • Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Cancer Journal (Sudbury, Mass.) 2007, 13: 257-62. PMID: 17762761, DOI: 10.1097/PPO.0b013e31813c1174.
  • Her signaling in pancreatic cancer.Burtness B. Her signaling in pancreatic cancer. Expert Opinion On Biological Therapy 2007, 7: 823-9. PMID: 17555368, DOI: 10.1517/14712598.7.6.823.
  • Bimodal population or pathologist artifact?Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B. Bimodal population or pathologist artifact? Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 2487-8. PMID: 17557963, DOI: 10.1200/JCO.2006.07.7537.
  • Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2007, 104: 341-9. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.
  • Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer.Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology 2007, 16: 553-8. PMID: 17372251, DOI: 10.1158/1055-9965.EPI-06-0121.
  • Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.
  • Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 2152-5. PMID: 17538157, DOI: 10.1200/JCO.2007.10.9017.
  • Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.Burtness B. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. Oncology (Williston Park, N.Y.) 2007, 21: 964-70; discussion 970, 974, 976-7. PMID: 17715697.
  • Advanced gastric cancer: new treatments raise new questions.Burtness BA. Advanced gastric cancer: new treatments raise new questions. Gastrointestinal Cancer Research : GCR 2008, 2: 158-9. PMID: 19259295, PMCID: PMC2633076.
  • The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clinical Advances In Hematology & Oncology : H&O 2008, 6: 742-50. PMID: 18997665, PMCID: PMC2745918.
  • Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray.Psyrri A, Egleston B, Weinberger P, Yu Z, Kowalski D, Sasaki C, Haffty B, Rimm D, Burtness B. Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology 2008, 17: 1486-92. PMID: 18559565, DOI: 10.1158/1055-9965.EPI-07-2684.
  • Viruses in head and neck cancers: prevention and therapy.Psyrri A, Burtness B. Viruses in head and neck cancers: prevention and therapy. Expert Review Of Anticancer Therapy 2008, 8: 1365-71. PMID: 18759688, DOI: 10.1586/14737140.8.9.1365.
  • Oropharyngeal cancer.Psyrri A, Prezas L, Burtness B. Oropharyngeal cancer. Clinical Advances In Hematology & Oncology : H&O 2008, 6: 604-12. PMID: 18820604.
  • Head and neck cancers.Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Goepfert H, Hicks WL, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. Journal Of The National Comprehensive Cancer Network : JNCCN 2008, 6: 646-95. PMID: 18691457, DOI: 10.6004/jnccn.2008.0051.
  • A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2008, 19: 977-83. PMID: 18296423, DOI: 10.1093/annonc/mdm591.
  • Head and neck cancer.Psyrri A, Burtness B, Harari PM, Vermorken JB, Licitra L, Sasaki CT. Head and neck cancer. Journal Of Oncology 2009, 2009: 358098. PMID: 20169126, PMCID: PMC2821645, DOI: 10.1155/2009/358098.
  • Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.Faller BA, Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics : Targets & Therapy 2009, 3: 419-28. PMID: 19774209, PMCID: PMC2747340.
  • NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal Of The National Comprehensive Cancer Network : JNCCN 2009, 7 Suppl 1: S5-21; quiz S22-4. PMID: 19470276, DOI: 10.6004/jnccn.2009.0074.
  • Targeting EGFR resistance networks in head and neck cancer.Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling 2009, 21: 1255-68. PMID: 19258037, PMCID: PMC2770888, DOI: 10.1016/j.cellsig.2009.02.021.
  • Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2009, 20: 1242-8. PMID: 19429872, PMCID: PMC2699385, DOI: 10.1093/annonc/mdn787.
  • Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. International Journal Of Radiation Oncology, Biology, Physics 2010, 78: 1020-5. PMID: 20231078, DOI: 10.1016/j.ijrobp.2009.09.003.
  • Defining venous involvement in borderline resectable pancreatic cancer.Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining venous involvement in borderline resectable pancreatic cancer. Annals Of Surgical Oncology 2010, 17: 2832-8. PMID: 20725860, DOI: 10.1245/s10434-010-1284-9.
  • Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology 2010, 19: 358-65. PMID: 20086114, PMCID: PMC2846615, DOI: 10.1158/1055-9965.EPI-09-0937.
  • Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2010, 16: 2427-34. PMID: 20371693, PMCID: PMC3030188, DOI: 10.1158/1078-0432.CCR-09-2658.
  • Targeted therapies: Molecular selection for 'smart' study design in lung cancer.Psyrri A, Burtness B. Targeted therapies: Molecular selection for 'smart' study design in lung cancer. Nature Reviews. Clinical Oncology 2010, 7: 621-2. PMID: 20981127, DOI: 10.1038/nrclinonc.2010.156.
  • Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased recurrences using intensity-modulated radiation therapy in the postoperative setting. American Journal Of Clinical Oncology 2010, 33: 599-603. PMID: 21063195, DOI: 10.1097/COC.0b013e3181c4c3cc.
  • Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates : Reviews And Commentaries In Antimicrobial And Anticancer Chemotherapy 2011, 14: 260-79. PMID: 21920801, PMCID: PMC3195944, DOI: 10.1016/j.drup.2011.08.002.
  • A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer 2011, 117: 3374-82. PMID: 21246525, PMCID: PMC3135694, DOI: 10.1002/cncr.25852.
  • Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. American Journal Of Clinical Oncology 2011, 34: 70-5. PMID: 20458210, PMCID: PMC3030655, DOI: 10.1097/COC.0b013e3181d2734a.
  • Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: the Fox Chase Cancer Center experience.Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: the Fox Chase Cancer Center experience. Head & Neck 2011, 33: 1433-40. PMID: 21928415, DOI: 10.1002/hed.21615.
  • Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma.Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2011, 17: 2947-54. PMID: 21355076, DOI: 10.1158/1078-0432.CCR-10-2040.
  • Commentary: bevacizumab and erlotinib with chemoradiation for head and neck cancer.Burtness B. Commentary: bevacizumab and erlotinib with chemoradiation for head and neck cancer. Cancer Journal (Sudbury, Mass.) 2011, 17: 273-5. PMID: 21952274, DOI: 10.1097/PPO.0b013e3182326944.
  • Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer.Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. International Journal Of Radiation Oncology, Biology, Physics 2011, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.
  • Significance of pathologic response to preoperative therapy in pancreatic cancer.Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of pathologic response to preoperative therapy in pancreatic cancer. Annals Of Surgical Oncology 2011, 18: 3601-7. PMID: 21947697, DOI: 10.1245/s10434-011-2086-4.
  • Head and neck cancers.Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. Journal Of The National Comprehensive Cancer Network : JNCCN 2011, 9: 596-650. PMID: 21636536, DOI: 10.6004/jnccn.2011.0053.
  • Multi-modality therapy for cancer of the esophagus and GE junction.Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.
  • Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer.Mehra R, Ang KK, Burtness B. Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Seminars In Radiation Oncology 2012, 22: 194-7. PMID: 22687943, DOI: 10.1016/j.semradonc.2012.03.003.
  • Informational Needs of Head and Neck Cancer Patients.Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA. Informational Needs of Head and Neck Cancer Patients. Health And Technology 2012, 2: 57-62. PMID: 22518350, PMCID: PMC3327509, DOI: 10.1007/s12553-012-0020-9.
  • Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma.Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. The Laryngoscope 2012, 122: 2762-8. PMID: 23086695, PMCID: PMC3574977, DOI: 10.1002/lary.23647.
  • Mucosal melanoma of the head and neck.Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F. Mucosal melanoma of the head and neck. Journal Of The National Comprehensive Cancer Network : JNCCN 2012, 10: 320-38. PMID: 22393194, DOI: 10.6004/jnccn.2012.0033.
  • Psychological functioning of caregivers for head and neck cancer patients.Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY. Psychological functioning of caregivers for head and neck cancer patients. Oral Oncology 2012, 48: 18-25. PMID: 22154127, PMCID: PMC3357183, DOI: 10.1016/j.oraloncology.2011.11.012.
  • A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. Journal Of Gastrointestinal Cancer 2012, 43: 562-9. PMID: 22294255, PMCID: PMC3400721, DOI: 10.1007/s12029-012-9368-3.
  • Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling".Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling". Science Signaling 2012, 5: lc5. PMID: 23233526, DOI: 10.1126/scisignal.2003734.
  • Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 2124-31. PMID: 23406730, DOI: 10.1093/annonc/mdt013.
  • Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discovery 2013, 3: 96-111. PMID: 23125191, PMCID: PMC3546138, DOI: 10.1158/2159-8290.CD-12-0031.
  • Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid : Official Journal Of The American Thyroid Association 2013, 23: 1099-105. PMID: 23421588, PMCID: PMC3770240, DOI: 10.1089/thy.2013.0027.
  • Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2013, 31: 1405-14. PMID: 23460714, PMCID: PMC3612594, DOI: 10.1200/JCO.2012.45.4272.
  • Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet. Oncology 2013, 14: e302-9. PMID: 23816296, DOI: 10.1016/S1470-2045(13)70085-8.
  • Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 6633-43. PMID: 24088734, PMCID: PMC4045641, DOI: 10.1158/1078-0432.CCR-13-0152.
  • Dysplasia at the margin? Investigating the case for subsequent therapy in 'low-risk' squamous cell carcinoma of the oral tongue.Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in 'low-risk' squamous cell carcinoma of the oral tongue. Oral Oncology 2013, 49: 1083-7. PMID: 24054332, PMCID: PMC4037753, DOI: 10.1016/j.oraloncology.2013.08.001.
  • Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns. Head & Neck 2013, 35: 160-4. PMID: 22302641, PMCID: PMC4037756, DOI: 10.1002/hed.22929.
  • Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. Journal Of The National Comprehensive Cancer Network : JNCCN 2013, 11: 917-23. PMID: 23946171, DOI: 10.6004/jnccn.2013.0113.
  • Esophageal carcinoma: are modern targeted therapies shaking the rock?Boland PM, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock? Current Opinion In Oncology 2013, 25: 417-24. PMID: 23680713, DOI: 10.1097/CCO.0b013e328362105e.
  • Aurora kinases in head and neck cancer.Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA. Aurora kinases in head and neck cancer. The Lancet. Oncology 2013, 14: e425-35. PMID: 23993387, PMCID: PMC4139969, DOI: 10.1016/S1470-2045(13)70128-1.
  • New directions in perioperative management of locally advanced esophagogastric cancer.Burtness B, Ilson D, Iqbal S. New directions in perioperative management of locally advanced esophagogastric cancer. American Society Of Clinical Oncology Educational Book / ASCO. American Society Of Clinical Oncology. Meeting 2014, e172-8. PMID: 24857100, DOI: 10.14694/EdBook_AM.2014.34.e172.
  • Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2014, 12: 1454-87. PMID: 25313184, DOI: 10.6004/jnccn.2014.0142.
  • Oropharyngeal squamous cell carcinoma treatment: current standards and future directions.Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment: current standards and future directions. Current Opinion In Oncology 2014, 26: 252-8. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/CCO.0000000000000072.
  • p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary.Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & Neck 2014, 36: 1677-84. PMID: 24115269, PMCID: PMC3972378, DOI: 10.1002/hed.23514.
  • On mentorship: lessons from my father.Burtness B. On mentorship: lessons from my father. Journal Of The National Comprehensive Cancer Network : JNCCN 2014, 12: 1651-2. PMID: 25361809, DOI: 10.6004/jnccn.2014.0162.
  • Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer. Journal Of Gastrointestinal Surgery : Official Journal Of The Society For Surgery Of The Alimentary Tract 2014, 18: 69-74. PMID: 24002765, DOI: 10.1007/s11605-013-2329-8.
  • Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer.Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein-Szanto AJ. Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer. Head & Neck 2014, 36: 1113-9. PMID: 23804308, PMCID: PMC4099415, DOI: 10.1002/hed.23421.
  • Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer.Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer 2014, 120: 840-7. PMID: 24352973, PMCID: PMC3951722, DOI: 10.1002/cncr.28482.
  • Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 2014, 15: 469. PMID: 25432788, PMCID: PMC4289298, DOI: 10.1186/1745-6215-15-469.
  • Targeted agents: management of dermatologic toxicities.Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network : JNCCN 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.
  • Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 5041-51. PMID: 25107914, PMCID: PMC4184913, DOI: 10.1158/1078-0432.CCR-14-0051.
  • Trends and variations in the use of adjuvant therapy for patients with head and neck cancer.Chen MM, Roman SA, Yarbrough WG, Burtness BA, Sosa JA, Judson BL. Trends and variations in the use of adjuvant therapy for patients with head and neck cancer. Cancer 2014, 120: 3353-60. PMID: 25042524, DOI: 10.1002/cncr.28870.
  • Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 3023-32. PMID: 24700741, PMCID: PMC4049169, DOI: 10.1158/1078-0432.CCR-14-0113.
  • Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2014, 25: 1410-6. PMID: 24799460, PMCID: PMC4071756, DOI: 10.1093/annonc/mdu167.
  • Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC). PloS One 2014, 9: e94273. PMID: 24722213, PMCID: PMC3983114, DOI: 10.1371/journal.pone.0094273.
  • A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2014, 25: 2230-2236. PMID: 25081901, PMCID: PMC4207729, DOI: 10.1093/annonc/mdu367.
  • Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2014, 25: 2036-41. PMID: 25009013, PMCID: PMC4176450, DOI: 10.1093/annonc/mdu248.
  • Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.Bhatia A, Burtness B. Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 3243-50. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/JCO.2015.61.2358.
  • Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Human Genetics 2015, 134: 497-507. PMID: 25108461, PMCID: PMC4324386, DOI: 10.1007/s00439-014-1470-0.
  • Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer.Burtness B. Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 3845-6. PMID: 26282638, DOI: 10.1200/JCO.2015.62.8487.
  • Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck.Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R. Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget 2015, 6: 18863-74. PMID: 26265441, PMCID: PMC4662460, DOI: 10.18632/oncotarget.4321.
  • Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. The Annals Of Thoracic Surgery 2015, 99: 270-6. PMID: 25440267, PMCID: PMC4284823, DOI: 10.1016/j.athoracsur.2014.08.033.
  • A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2015, 21: 1566-73. PMID: 25573383, PMCID: PMC6607903, DOI: 10.1158/1078-0432.CCR-14-2820.
  • EGFR-directed antibodies increase the risk of severe infection in cancer patients.Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015, 13: 37. PMID: 25857245, PMCID: PMC4336483, DOI: 10.1186/s12916-015-0276-9.
  • Head and Neck Cancers, Version 1.2015.Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 847-55; quiz 856. PMID: 26150579, PMCID: PMC4976490, DOI: 10.6004/jnccn.2015.0102.
  • National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database.Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-35. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.
  • EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Molecular Cancer Therapeutics 2016, 15: 2486-2497. PMID: 27507850, PMCID: PMC5522587, DOI: 10.1158/1535-7163.MCT-16-0243.
  • Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. The Lancet. Oncology 2016, 17: 956-965. PMID: 27247226, DOI: 10.1016/S1470-2045(16)30066-3.
  • Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. American Journal Of Clinical Oncology 2016, 39: 340-5. PMID: 24685886, PMCID: PMC4177955, DOI: 10.1097/COC.0000000000000068.
  • Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 3838-3845. PMID: 27646946, PMCID: PMC6804896, DOI: 10.1200/JCO.2016.68.1478.
  • Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base.Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL. Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base. Cancer 2016, 122: 1853-60. PMID: 27019213, DOI: 10.1002/cncr.29962.
  • Treatment de-intensification strategies for head and neck cancer.Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. European Journal Of Cancer (Oxford, England : 1990) 2016, 68: 125-133. PMID: 27755996, PMCID: PMC5734050, DOI: 10.1016/j.ejca.2016.09.006.
  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet. Oncology 2016, 17: 717-726. PMID: 27157491, DOI: 10.1016/S1470-2045(16)00175-3.
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 2736-42. PMID: 27382098, PMCID: PMC5019745, DOI: 10.1200/JCO.2015.65.5092.
  • Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncology 2016, 62: 147-148. PMID: 27776933, DOI: 10.1016/j.oraloncology.2016.10.007.
  • Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.Husain ZA, Burtness BA, Decker RH. Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 396-8. PMID: 26644528, DOI: 10.1200/JCO.2015.64.7586.
  • Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity.Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL. Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity. Cancer 2016, 122: 3624-3631. PMID: 27479645, DOI: 10.1002/cncr.30227.
  • Introducing cancers of the head and neck, a new open access journal.Burtness B. Introducing cancers of the head and neck, a new open access journal. Cancers Of The Head & Neck 2016, 1: 3. PMID: 31093333, PMCID: PMC6457142, DOI: 10.1186/s41199-016-0001-1.
  • Pretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study.Subramanian HE, Park HS, Barbieri A, Mahajan A, Judson BL, Mehra S, Yarbrough WG, Burtness BA, Husain ZA. Pretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study. Cancers Of The Head & Neck 2016, 1: 7. PMID: 31093337, PMCID: PMC6460847, DOI: 10.1186/s41199-016-0008-7.
  • Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma.Psyrri A, Rampias T, Burtness B. Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 125. PMID: 27607105, DOI: 10.1001/jamaoncol.2016.3409.
  • Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.CCR-17-1438.
  • Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck.Parameswaran J, Burtness B. Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. International Journal Of Radiation Oncology, Biology, Physics 2017, 98: 969-973. PMID: 28721906, DOI: 10.1016/j.ijrobp.2017.03.003.
  • E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 490-497. PMID: 28029303, PMCID: PMC5455313, DOI: 10.1200/JCO.2016.68.3300.
  • Reply to A. Garden et al.Marur S, Li S, Cmelak A, Burtness B. Reply to A. Garden et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 1970-1971. PMID: 28430530, DOI: 10.1200/JCO.2017.72.8279.
  • NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications 2017, 8: 1772. PMID: 29176703, PMCID: PMC5701248, DOI: 10.1038/s41467-017-01877-7.
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2017, 123: 1259-1271. PMID: 27906454, PMCID: PMC5705038, DOI: 10.1002/cncr.30449.
  • Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. American Journal Of Clinical Oncology 2017, 40: 393-398. PMID: 26986978, PMCID: PMC5026539, DOI: 10.1097/COC.0000000000000171.
  • The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 2017, 123: 2762-2772. PMID: 28323338, DOI: 10.1002/cncr.30598.
  • Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 2017, 123: 4653-4662. PMID: 28786105, PMCID: PMC5693641, DOI: 10.1002/cncr.30920.
  • Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9 PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.
  • Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification.Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification. Ear, Nose, & Throat Journal 2017, 96: E12-E18. PMID: 28719713, PMCID: PMC7549076, DOI: 10.1177/014556131709600703.
  • NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 761-770. PMID: 28596256, DOI: 10.6004/jnccn.2017.0101.
  • A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 358-365. PMID: 27737449, DOI: 10.1001/jamaoncol.2016.4581.
  • The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation.Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA. The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. Practical Radiation Oncology 2017, 7: e317-e321. PMID: 28356201, DOI: 10.1016/j.prro.2017.02.004.
  • Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment.Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.
  • Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials.Marur S, Cmelak AJ, Burtness B. Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 1968-1969. PMID: 28430529, DOI: 10.1200/JCO.2017.72.2918.
  • TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer 2017, 123: 1778-1790. PMID: 28295222, PMCID: PMC5419871, DOI: 10.1002/cncr.30570.
  • Comparison of Survival Outcomes Among Human Papillomavirus-Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study.Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z. Comparison of Survival Outcomes Among Human Papillomavirus-Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study. JAMA Oncology 2017, 3: 1107-1111. PMID: 28056116, PMCID: PMC5824218, DOI: 10.1001/jamaoncol.2016.5769.
  • Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival.Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal Of The National Cancer Institute 2017, 109 PMID: 28521361, DOI: 10.1093/jnci/djx042.
  • Biomarker driven treatment of head and neck squamous cell cancer.Eze N, Lo YC, Burtness B. Biomarker driven treatment of head and neck squamous cell cancer. Cancers Of The Head & Neck 2017, 2: 6. PMID: 31093353, PMCID: PMC6460531, DOI: 10.1186/s41199-017-0025-1.
  • Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 2526-2532. PMID: 28961833, PMCID: PMC5834024, DOI: 10.1093/annonc/mdx344.
  • Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.Bhatia AK, Burtness BA, Decker RH. Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 1269-1271. PMID: 29547345, DOI: 10.1200/JCO.2018.77.7987.
  • Response.Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Response. Journal Of The National Cancer Institute 2018, 110: 433-434. PMID: 29121329, DOI: 10.1093/jnci/djx230.
  • The tumor genome in human immunodeficiency virus-related head and neck cancer: Exploitable targets?Burtness B. The tumor genome in human immunodeficiency virus-related head and neck cancer: Exploitable targets? Cancer 2018, 124: 14-17. PMID: 29053184, DOI: 10.1002/cncr.31059.
  • Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncology 2018, 79: 64-70. PMID: 29598952, DOI: 10.1016/j.oraloncology.2018.02.017.
  • Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database.Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.
  • NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 479-490. PMID: 29752322, DOI: 10.6004/jnccn.2018.0026.
  • National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation.Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S. National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. Oral Oncology 2018, 82: 122-130. PMID: 29909886, DOI: 10.1016/j.oraloncology.2018.02.010.
  • Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal Of Cancer 2018, 119: 153-159. PMID: 29955135, PMCID: PMC6048158, DOI: 10.1038/s41416-018-0131-9.
  • Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations.Morse E, Judson B, Husain Z, Burtness B, Yarbrough WG, Sasaki C, Cheraghlou S, Mehra S. Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations. Otolaryngology--head And Neck Surgery : Official Journal Of American Academy Of Otolaryngology-Head And Neck Surgery 2018, 194599818779052. PMID: 30060700, DOI: 10.1177/0194599818779052.
  • Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma.Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.
  • Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks.Kann BH, Aneja S, Loganadane GV, Kelly JR, Smith SM, Decker RH, Yu JB, Park HS, Yarbrough WG, Malhotra A, Burtness BA, Husain ZA. Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks. Scientific Reports 2018, 8: 14036. PMID: 30232350, PMCID: PMC6145900, DOI: 10.1038/s41598-018-32441-y.
  • HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes.Cheraghlou S, Torabi SJ, Husain ZA, Otremba MD, Osborn HA, Mehra S, Yarbrough WG, Burtness BA, Judson BL. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. The Laryngoscope 2019, 129: 684-691. PMID: 30151832, DOI: 10.1002/lary.27475.
  • Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019, 393: 40-50. PMID: 30449625, PMCID: PMC6541928, DOI: 10.1016/S0140-6736(18)32779-X.
  • APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene 2019, 38: 3475-3487. PMID: 30647454, PMCID: PMC6499643, DOI: 10.1038/s41388-018-0657-6.
  • Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019, 393: 156-167. PMID: 30509740, DOI: 10.1016/S0140-6736(18)31999-8.
  • Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness BA. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 3430-3442. PMID: 30755439, PMCID: PMC6548643, DOI: 10.1158/1078-0432.CCR-18-0440.
  • Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, Husain ZA. Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer 2019, 125: 2018-2026. PMID: 30748002, PMCID: PMC6541535, DOI: 10.1002/cncr.32001.
  • Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head & Neck 2019, 41: 1928-1934. PMID: 30758123, PMCID: PMC6542589, DOI: 10.1002/hed.25634.
  • PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Oral Oncology 2019, 91: 69-78. PMID: 30926065, PMCID: PMC6855599, DOI: 10.1016/j.oraloncology.2019.02.026.
  • Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion.Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, Le QT, Semrad TJ, Siu LL, Ridge JA. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 1578-1589. PMID: 31021656, DOI: 10.1200/JCO.19.00441.
  • Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment.Lee NCJ, Eskander A, Park HS, Mehra S, Burtness BA, Husain Z. Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Cancer 2019, 125: 2975-2983. PMID: 31090934, DOI: 10.1002/cncr.32161.
  • Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book / ASCO. American Society Of Clinical Oncology. Meeting 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/EDBK_238315.
  • Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment.Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL. Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. Oral Oncology 2019, 94: 32-40. PMID: 31178210, DOI: 10.1016/j.oraloncology.2019.05.009.
  • The changing therapeutic landscape of head and neck cancer.Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nature Reviews. Clinical Oncology 2019, 16: 669-683. PMID: 31189965, DOI: 10.1038/s41571-019-0227-z.
  • Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Martins Segalla JG, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA Oncology 2019, 5: 1170-1180. PMID: 31194247, PMCID: PMC6567846, DOI: 10.1001/jamaoncol.2019.1146.
  • Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.Baro M, Lopez Sambrooks C, Burtness BA, Lemmon MA, Contessa JN. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics 2019, 18: 2124-2134. PMID: 31387891, PMCID: PMC6825559, DOI: 10.1158/1535-7163.MCT-19-0163.
  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). Journal For Immunotherapy Of Cancer 2019, 7: 184. PMID: 31307547, PMCID: PMC6632213, DOI: 10.1186/s40425-019-0662-5.
  • Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy.Loganadane G, Kann BH, Park HS, Johnson SB, Mehra S, Judson BL, Bhatia A, Belkacemi Y, Yarbrough WG, Burtness B, Husain ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.
  • Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 3266-3274. PMID: 31618129, PMCID: PMC6980834, DOI: 10.1200/JCO.19.00555.
  • Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition.Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.
  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019, 394: 1915-1928. PMID: 31679945, DOI: 10.1016/S0140-6736(19)32591-7.
  • Immunotherapy for head and neck cancer: Recent advances and future directions.Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncology 2019, 99: 104460. PMID: 31683169, PMCID: PMC7749717, DOI: 10.1016/j.oraloncology.2019.104460.
  • Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report.Xiang JJ, Uy NF, Minja FJ, Verter EE, Burtness BA. Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report. The Laryngoscope 2020, 130: 907-910. PMID: 31058321, DOI: 10.1002/lary.28042.
  • Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma.Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, Park HS, Yu JB, Yarbrough WG, Burtness BA, Husain ZA, Aneja S. Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 1304-1311. PMID: 31815574, DOI: 10.1200/JCO.19.02031.
  • Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201.Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 472-479. PMID: 31815582, PMCID: PMC7007287, DOI: 10.1200/JCO.19.00925.
  • Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer.Saeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.
  • Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer.Deneka AY, Einarson MB, Bennett J, Nikonova AS, Elmekawy M, Zhou Y, Lee JW, Burtness BA, Golemis EA. Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers 2020, 12 PMID: 32012873, PMCID: PMC7072436, DOI: 10.3390/cancers12020306.
  • PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma.Haider SP, Mahajan A, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kucukkaya AS, Kann BH, Judson BL, Prasad ML, Burtness B, Payabvash S. PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2978-2991. PMID: 32399621, DOI: 10.1007/s00259-020-04839-2.
  • Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas.Haider SP, Burtness B, Yarbrough WG, Payabvash S. Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas. Cancers Of The Head & Neck 2020, 5: 6. PMID: 32391171, PMCID: PMC7197186, DOI: 10.1186/s41199-020-00053-7.
  • Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.Machiels JP, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, Alves GV, Figueiredo Lima IP, Pointreau Y, M Hughes BG, Aksoy S, Hetnal M, Ge JY, Brown H, Cheng J, Bidadi B, Siu LL. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncology (London, England) 2020, 16: 1235-1243. PMID: 32490686, DOI: 10.2217/fon-2020-0184.
  • High Dose Cisplatin: Still the One?Husain ZA, Burtness BA. High Dose Cisplatin: Still the One? International Journal Of Radiation Oncology, Biology, Physics 2020, 107: 615-616. PMID: 32589986, DOI: 10.1016/j.ijrobp.2019.09.026.
  • Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma.Haider SP, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kann BH, Judson BL, Prasad ML, Burtness B, Mahajan A, Payabvash S. Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma. Cancers 2020, 12 PMID: 32635216, PMCID: PMC7407414, DOI: 10.3390/cancers12071778.
  • A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311.Ferris RL, Flamand Y, Holsinger FC, Weinstein GS, Quon H, Mehra R, Garcia JJ, Hinni ML, Gross ND, Sturgis EM, Duvvuri U, Méndez E, Ridge JA, Magnuson JS, Higgins KA, Patel MR, Smith RB, Karakla DW, Kupferman ME, Malone JP, Judson BL, Richmon J, Boyle JO, Bayon R, O'Malley BW, Ozer E, Thomas GR, Koch WM, Bell RB, Saba NF, Li S, Sigurdson ER, Burtness B. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncology 2020, 110: 104797. PMID: 32679405, PMCID: PMC7771718, DOI: 10.1016/j.oraloncology.2020.104797.
  • Further clinical interpretation and implications of KEYNOTE-048 findings - Authors' reply.Burtness B, Zhang Y, Harrington KJ, Rischin D. Further clinical interpretation and implications of KEYNOTE-048 findings - Authors' reply. Lancet 2020, 396: 379-380. PMID: 32771104, DOI: 10.1016/S0140-6736(20)30900-4.
  • Predictive classifier for intensive treatment of head and neck cancer.Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le QT, Gregoire V, Overgaard J, Hackshaw A, Zackrisson B, Parmar MKB, Burtness BA, Ghi MG, Sanguineti G, O'Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Michiels S, Pignon JP, Mell LK. Predictive classifier for intensive treatment of head and neck cancer. Cancer 2020, 126: 5263-5273. PMID: 33017867, DOI: 10.1002/cncr.33212.
  • Head and neck squamous cell carcinoma.Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature Reviews. Disease Primers 2020, 6: 92. PMID: 33243986, PMCID: PMC7944998, DOI: 10.1038/s41572-020-00224-3.
  • ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer.Cmelak A, Dietrich MS, Li S, Ridner S, Forastiere A, Burtness BA, Cella D, Murphy BA. ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer. Cancers Of The Head & Neck 2020, 5: 12. PMID: 33353553, PMCID: PMC7756946, DOI: 10.1186/s41199-020-00059-1.
  • Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal Of The National Cancer Institute 2021, 113: 171-181. PMID: 32407532, PMCID: PMC7850527, DOI: 10.1093/jnci/djaa063.
  • Reply to "Keynote 48: Is it really for everyone?"Burtness B, Ge J. Reply to "Keynote 48: Is it really for everyone?" Oral Oncology 2021, 112: 104983. PMID: 33032941, DOI: 10.1016/j.oraloncology.2020.104983.
  • Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomics.Haider SP, Sharaf K, Zeevi T, Baumeister P, Reichel C, Forghani R, Kann BH, Petukhova A, Judson BL, Prasad ML, Liu C, Burtness B, Mahajan A, Payabvash S. Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomics. Translational Oncology 2021, 14: 100906. PMID: 33075658, PMCID: PMC7568193, DOI: 10.1016/j.tranon.2020.100906.
  • Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck.Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology--head And Neck Surgery : Official Journal Of American Academy Of Otolaryngology-Head And Neck Surgery 2021, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.
  • Survivin expression and impact on head and neck cancer outcomes.Khan SA, Burke M, Zhu F, Yang DH, Dubyk C, Mehra R, Lango MJ, Ridge JA, Sher DJ, Burtness B. Survivin expression and impact on head and neck cancer outcomes. Oral Oncology 2021, 112: 105049. PMID: 33221541, DOI: 10.1016/j.oraloncology.2020.105049.
  • Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen EEW, Harrington K, Soulières D, Le Tourneau C, Licitra L, Burtness B, Swaby R. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2021, 34: 532-541. PMID: 33239737, DOI: 10.1038/s41379-020-00710-9.
  • Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer.Burtness B, Contessa J. Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer. Journal Of The National Cancer Institute 2021, 113: 652-653. PMID: 33429429, PMCID: PMC8168139, DOI: 10.1093/jnci/djaa187.
  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Ruo Redda MG, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy And Oncology : Journal Of The European Society For Therapeutic Radiology And Oncology 2021, 156: 281-293. PMID: 33515668, PMCID: PMC8386522, DOI: 10.1016/j.radonc.2021.01.013.
  • STING enhances cell death through regulation of reactive oxygen species and DNA damage.Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 2021, 12: 2327. PMID: 33875663, PMCID: PMC8055995, DOI: 10.1038/s41467-021-22572-8.
  • Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer.Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.
  • Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study.Xiao C, Beitler JJ, Peng G, Levine ME, Conneely KN, Zhao H, Felger JC, Wommack EC, Chico CE, Jeon S, Higgins KA, Shin DM, Saba NF, Burtness BA, Bruner DW, Miller AH. Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study. Cancer 2021, 127: 3361-3371. PMID: 34027995, DOI: 10.1002/cncr.33641.
  • Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?Cmelak AJ, Ferris RL, Chen AM, Seiwert T, Burtness B. Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable? Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2021, 39: 2732-2733. PMID: 34043410, DOI: 10.1200/JCO.21.00594.

Clinical Trials

ConditionsStudy Title
Larynx; Lip, Oral Cavity and PharynxA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Larynx; Lip, Oral Cavity and PharynxA Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)
Corpus Uteri; Larynx; Lung; Soft Tissue; Unknown SitesA Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Thyroid; Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Esophagus; Larynx; Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
Other SkinA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Lip, Oral Cavity and PharynxPhase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Larynx; Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Anus; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Kaposi's sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, skin; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Cervix; Urinary BladderNCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Larynx; Lip, Oral Cavity and PharynxPhase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Larynx; Lip, Oral Cavity and PharynxRadiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
Lip, Oral Cavity and PharynxIndividualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Edit Profile